Shares shifted sharply higher as ADMA Biologics jumped 10% to $10.19 on August 7, two days after its second-quarter earnings revealed a company being remade by a single product. Total revenue rose just 2% year-over-year to $124.4 million , slightly below the consensus estimate of $131.66 million . But investors looked past the top-line miss and zeroed in on profitability: GAAP basic EPS hit $0.17, up 17% year-over-year , beating the $0.17 Street estimate while margins and cash earnings surged.

  • The Star Product Is Doing the Heavy Lifting — Almost All of It. ADMA's higher-margin immune-deficiency treatment, ASCENIV, generated roughly 83% of total quarterly revenue . ASCENIV revenue hit $102.9 million, up 24% year-over-year, while BIVIGAM, the company's older immune therapy, fell 49% . ASCENIV's $19.6 million gain nearly offset BIVIGAM's $18.3 million decline , leaving overall growth paper-thin. The question is whether ASCENIV can keep growing fast enough to compensate for a collapsing secondary revenue stream.

  • Margins Tell a Better Story Than Revenue. Gross profit surged to $86.3 million from $67.2 million a year ago, pushing gross margin — the percentage of each dollar kept after production costs — to 69% from 55% . This expansion came from ASCENIV's larger share of sales and a yield-enhanced manufacturing process that squeezes more product from each batch of plasma. Adjusted EBITDA (a proxy for operating cash profits) rose 22% to $61.8 million , far outpacing revenue growth.

  • The BIVIGAM Problem Isn't Going Away. Persistent pricing pressure and competitive intensity in the standard immune-globulin market are expected to continue weakening BIVIGAM . ADMA already slashed its full-year 2026 revenue guidance from over $635 million to $530–$560 million after Q1. Management reiterated that lowered guidance this quarter , signaling no improvement in the competitive picture.

  • The Stock Is Still Down More Than 50% This Year — Analysts See Far More Upside. Shares are down over 50% year-to-date despite consistent ASCENIV momentum. The average analyst price target sits at $17.00, with a high of $21.00 — roughly 67% above today's price. The gap reflects a market still skeptical that one product can sustain a full recovery, even as that product's economics get dramatically better every quarter.